The factors associated with longitudinal changes in liver stiffness in patients with chronic hepatitis B
- Authors
- Yo, In Ku; Kwon, Oh Sang; Park, Jin Woong; Lee, Jong Joon; Lee, Jung Hyun; Won, In Sik; Na, Sun Young; Jang, Pil Kyu; Park, Pyung Hwa; Choi, Duck Joo; Kim, Yun Soo; Kim, Ju Hyun
- Issue Date
- Mar-2015
- Publisher
- KOREAN ASSOC STUDY LIVER
- Keywords
- Chronic hepatitis B; Hepatic fibrosis; Liver stiffness; Transient elastography
- Citation
- CLINICAL AND MOLECULAR HEPATOLOGY, v.21, no.1, pp.32 - 40
- Journal Title
- CLINICAL AND MOLECULAR HEPATOLOGY
- Volume
- 21
- Number
- 1
- Start Page
- 32
- End Page
- 40
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/10738
- DOI
- 10.3350/cmh.2015.21.1.32
- ISSN
- 2287-2728
- Abstract
- Background/Aims: Liver stiffness (LS) as assessed by transient elastography (TE) can change longitudinally in patients with chronic hepatitis B (CHB). The aim of this study was to identify the factors that improve LS. Methods: Between April 2007 and December 2012, 151 patients with CHB who underwent two TE procedures with an interval of about 2 years were enrolled. Ninety-six of the 151 patients were treated with nucleos(t) ide analogues [the antiviral therapy (+) group], while the remaining 55 patients were not [the antiviral therapy (-) group]. The two groups of patients were stratified according to whether they exhibited an improvement or a deterioration in LS during the study period (defined as an LS change of <= 0 or >0 kPa, respectively, over a 1-year period), and their data were compared. Results: No differences were observed between the antiviral therapy (+) and (-) groups with respect to either their clinical characteristics or their initial LS. The observed LS improvement was significantly greater in the antiviral therapy (+) group than in the antiviral therapy (-) group (-3.0 vs. 0.98 kPa, P=0.011). In the antiviral therapy (+) group, the initial LS was higher in the LS improvement group (n=63) than in the LS deterioration group (n=33; 7.9 vs. 4.8 kPa, P<0.001). However, there were no differences in any other clinical characteristic. In the antiviral therapy (-) group, the initial LS was also higher in the LS improvement group (n=29) than in the LS deterioration group (n=26; 8.3 vs. 6.5 kPa, P=0.021), with no differences in any other clinical characteristic. Conclusions: A higher initial LS was the only factor associated with LS improvement in patients with CHB in this study.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 법과대학 > 법학과 > 1. Journal Articles
- 의과대학 > 의학과 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/10738)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.